Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05444244 · ClinicalTrials.gov registry record · NA

A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research

A NA study of Alzheimer Disease and Dementia, sponsored by University of Wisconsin, Madison.

Completed
Registry status
NA
Development phase
182
Enrollment target
1
Study location

NCT05444244: Completed NA study of Alzheimer Disease and Dementia, sponsored by University of Wisconsin, Madison.

NCT05444244 is a NA study of Alzheimer Disease and Dementia that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 182 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05444244, a NA study of Alzheimer Disease and Dementia, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
NA
Development phase
182 participants
Enrollment target
1
Study location

Study Summary

Despite well-documented disparities in Alzheimer's disease and related dementia (AD) prevalence, incidence, treatment, and mortality, individuals from disadvantaged backgrounds (e.g. racial/ethnic minorities and socioeconomically disadvantaged persons) are under-represented in clinical research. Existing research recruitment approaches are rarely designed to accommodate the priorities, concerns, and constraints relevant to participants from diverse backgrounds. To address these gaps, the investigators developed a research recruitment and engagement model, the Participant Oriented Research Engagement Model that centers and prioritizes relational aspects of research engagement, research participant needs, and systematically address socioeconomic determinants (i.e. unmet needs) that may limit accessibility of research. The investigators propose to test the effectiveness of the Brain Health Community (BHC) Registry recruitment and engagement intervention, as compared to standard research recruitment strategies in modifying enrollment rates, participant satisfaction, and engagement. The investigators hypothesize that the BHC Registry will yield greater enrollment rates, higher satisfaction, and better ratings of relational engagement.

Primary Outcome

Number of participants enrolled in the Brain Health Community Registry

Interventions

  • OTHER Relational Research Recruitment and Engagement Intervention

Study Locations (1)

Wisconsin

  • University of Wisconsin-Madison - Madison

Trial Details

FieldValue
Enrollment Target 182 participants
Start Date 2022-08-01
Est. Completion 2023-05-31
Phase NA
University of Wisconsin, Madison

1,039 total trials

What the finished NCT05444244 record still lists

NCT05444244 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower).

The record links to 5 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Relational Research Recruitment and Engagement Intervention is the first listed.

NCT05444244 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT05444244 about?

NCT05444244 is a clinical study titled "A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research". Despite well-documented disparities in Alzheimer's disease and related dementia (AD) prevalence, incidence, treatment, and mortality, individuals from disadvantaged backgrounds (e.g. racial/ethnic minorities and socioeconomically disadvantaged persons) are under-represented in clinical research. Exi...

What is the current status of trial NCT05444244?

This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2022-08-01. Estimated completion is 2023-05-31.

What conditions does trial NCT05444244 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Cognitive Dysfunction, Frontotemporal Dementia, Lewy Body Disease.

What interventions are being tested in trial NCT05444244?

The interventions under investigation include: Relational Research Recruitment and Engagement Intervention (OTHER).

Who is sponsoring clinical trial NCT05444244?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05444244 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05444244's enrollment target sits among peer trials

182 116th of 306 higher than 190 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03897998 · 182 participants · Phase 2

    Neural Correlates of Hypoalgesia Driven by Observation

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  • NCT04323735 · 182 participants · Phase 2

    Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

  • NCT05606731 · 182 participants · NA

    Family Intervention to Prevent Childhood Obesity

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05444244, the US trial registry maintained by the National Library of Medicine. NCT05444244 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.